MTND2P14

Across TCGA pan-cancer cohorts, MTND2P14 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated MTND2P14 data layer.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher MTND2P14 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTND2P14 expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

READ, UCEC, and SARC are the cancer types where MTND2P14 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Tertile	III,IV	0.289	0.901	<.001	99	view →
UCEC	OS	Tertile	IV	0.308	0.748	.009	60	view →
SARC	OS	Tertile	All	0.142	0.750	<.001	36	view →
BRCA	DFS	Tertile	II,III,IV	0.759	0.892	.015	24	view →
ESCA	OS	Tertile	III,IV	1.000	0.371	.032	24	view →
UVM	DFS	Tertile	III,IV	0.071	0.636	<.001	18	view →
THCA	DFS	Tertile	III,IV	0.081	0.738	<.001	9	view →
STAD	OS	Quartile	IV	0.116	0.449	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MTND2P14–READ (OS)

Open the READ breakdown →